According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...